Israel-based life sciences investment fund aMoon has signed an exclusive agreement with Credit Suisse.
Through the partnership, Credit Suisse will present aMoon II to its clients and institutional investors in Europe to raise $250 million – $100 million exclusive access to $250 million of investments into the aMoon for Europe to raise $250 million: $100 million from institutional investors and a further $150 million from family office investors.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
This strategic venture was realized following the April closing of aMoon II at $200 million, out of a targeted total of $500 million, from the founder Marius Nacht himself and other investors in Israel, the US and Canada.
aMoon II which will be launched in Tel Aviv this evening is investing in mid- to late-stage health tech companies and is oriented towards closing a gap for underfunded, undervalued companies in global hubs with strong health tech ecosystems in Israel, the United States and Europe. The fund’s three areas of focus are digital health, medical devices and biopharma.
Marius Nacht target 500 million would make aMoon the largest Israeli life sciences investment fund, surpassing OrbiMed $307 million life science investment fund.
Dr. Yair Schindel, Co-Founder & Managing Partner of aMoon said “This strategic partnership is perfectly timed to leverage the growing convergence of technology and healthcare. Breakthrough scientific research, innovative technology, and decades of digital health records make Israel an ideal launchpad for leading this global transformation in healthcare. This will generate deep value for our investors and positively impact the lives of millions of patients.”
Michel Degen, CEO of Credit Suisse Asset Management Switzerland and EMEA, added: “It is critical that, disruptive businesses, which are committed to resolving some of the healthcare sector’s most pressing issues, receive access to venture capital and the liquidity they need. We are therefore delighted to enter into a strategic partnership with aMoon, a leader in health tech and life sciences investing.”
Credit Suisse Asset Management pursues innovative investment solutions to access this fast-growing field as evidenced recently by a successful launch of its digital health investment strategy.
